|

S-488210/S-488211 Clinical Trials

1 actively recruiting trial

Also known as: S-488210/Montanide, S-488211/Montanide

Pipeline

Phase 1/2: 1

Top Sponsors

  • University College, London1

Indications

  • Bladder Cancer1
  • Cancer1

Other1 trial

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.